Abstract
Insulin-like growth factor-1 (IGF-1) plays an important growth-promoting effect by activating the PI3K/Akt signalling pathway, inhibiting apoptotic pathways and mediating mitogenic actions. Tyrphostin AG 1024, one selective inhibitor of IGF-1R, was used to evaluate effects on proliferation, radiosensitivity, and radiation-induced cell apoptosis in a human breast cancer cell line MCF-7. Exposure to Tyrphostin AG 1024 inhibited proliferation and induced apoptosis in a time-dependent manner, and the degree of growth inhibition for IC20 plus irradiation (4 Gy) was up to 50% compared to the control. Examination of Tyrphostin AG 1024 effects on radiation response demonstrated a marked enhancement in radiosensitivity and amplification of radiation-induced apoptosis. Western blot analysis indicated that Tyrphostin AG 1024-induced apoptosis was associated with a downregulation of expression of phospho-Akt1, increased expression of Bax, p53 and p21, and a decreased expression of bcl-2 expression, especially when combined with irradiation. To our knowledge, this is the first report showing that an IGF-1 inhibitor was able to markedly increase the response of tumour cells to ionizing radiation. These results suggest that Tyrphostin AG 1024 could be used as a potential therapeutic agent in combination with irradiation. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baserga R (1995) The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res 55: 249–252
Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B (1997) The IGF-1 receptor in cell growth, transformation and apoptosis. Biochim Acta 1332: 105–126
Blume-Jensen P and Hunter T (2001) Oncogenic kinase signaling. Nature 411: 355–365
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B and Seizinger BR (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646–649
Cianfarani S and Rossi P (1997) Neuroblastoma and insulin-like growth factor system. Eur J Pediatr 156: 256–261
Coleman CN and Stevenson MA (1996) Biologic basis for radiation oncology. Oncology 10: 399–411
Christofori G, Naik P and Hanahan D (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414–418
Dupont J, Karas M and LeRoiths D (2000) The potentiation of estrogen on insulin-like growth factor I action in MCF7 human breast cancer cells includes cell cycle components. J Biol Chem 275: 35893–35901
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) Wafl, a potential mediator of p53 tumor suppression. Cell 75: 817–825
Fowler JF and Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23: 457–467
Gazit A, Yaish P and Gilon C (1989) Tyrphostins I. Synthesis and biological activity of protein tyrosine linase inhibitors. J Med Chem 32: 2344–2352
Huang SM, Bock JM and Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935–1940
Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34
Kiess W, Koepf G, Christiansen H and Blum WF (1997) Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-1 receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept 72: 19–29
Kim TK (1997) In vitro transcriptional activation of p21 promoter by p53. Biochem Biophys Res Commun 234: 300–302
Lee AV, Gooch JL, Oesterreich S, Guler RL and Yee D (2000) Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol Cell Biol 20: 1489–1496
Liu X, Turbyville T, Fritz A and Whitesell L (1998) Inhibition of insulin-like growth factor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58: 5432–5438
LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr. (1995) Molecular and cellular aspects of the insulin-like growth factor 1 receptor. Endocr Rev 16: 143–163
Levitzki A and Gazit A (1995) Tyropsine kinase inhibition: an approach to drug development. Science 267: 1782–1788
Lopacznski W (1999) Different regulation of signaling pathways for insulin and insulin like growth factor I. Acta Biochim Pol 46: 51–60
Maestro R, Gloghini A, Doglioni C, Piccinin S, Vukosavljevic T, Gasparotto D, Carbone A and Biocchi M (1997) Human non-Hodgkin’s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89: 2523–2528
Minshall C, Arkins S, Straza J, Conners J, Dantzer R and Freund GG et al (1997) IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol 159: 1225–1232
Monno S, Newman MV, Cook M and Lowe WL Jr. (2000) Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF7 breast cancer cells. Endocrinology 141, (2): 544–550
Ohlsson C, Kley N, Werner H and LeRoith D (1998) p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139: 1101–1107
Parrizas M and LeRoith D (1997) Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138: 1355–1358
Rubin R and Baserga R (1995) Biology of desease: insulin-like growth factor-1 receptor. Lab Invest 73: 311–331
Schmitz G (1991) Nonradioactive labelling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Anal Biochem 192: 222–231
Sphepherd PR, Withers DJ and Siddle K (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J 333: 471–470
Scotlandi K, Benini S, Nanni P, Lolliai P, Nicoletti G, Landuzzi L, Serra M, Manara C, Picci P and Baldini N (1998) Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing’s sarcoma in athymic mice. Cancer Res 58: 4127–4131
Shevelev A, Burfeind P, Schulze E, Rininsland F, Johnson T, Trojan J, Chernicky C, Hélène C, Ilan J and Ilan J (1997) Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model. Cancer Gene Ther 4: 105–112
Sullivan KA, Castle VP, Hanash SM and Feldman EL (1995) Insulin-like growth factor II in the pathogenesis of human neuroblastoma. Am J Pathol 147: 1790–1798
Takahashi K and Suzuki K (1993) Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 55: 453–458
Trojan J, Johnson T, Rudin S, Blossey B, Kelley K, Shevelev A, Abdul-Karim F, Anthony D, Tykocinski M, Ilan J and Ilan J (1994) Gene therapy of murine teratocarcinoma: sepatate functions for insulin-like growth factors I and II in immunogenicity and differentiation. Proc Natl Acad Sci USA 91: 6088–6092
Wang L, Ma W, Markovich R, Lee WL and Wang PH (1998) Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 139: 1354–1360
Werner H, Karnieli E, Rauscher FJ and LeRoith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318–8323
Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M and Seely BL (1996) Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 56: 2781–2788
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366(6456): 701–704
Yuan Z, Sun MFeldman R, Wang G, Ma X, Jiang C, Coppola D, Nicosia A and Cheng J (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324–2330
Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN and Fornace AJ et al (1996) Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res 56: 1367–1373
Zhang L, Zhan Q, Zhan S, Kashanchi F, Fornace AJ Jr. and Seth P et al (1998) p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 17: 125–131
Zumkeller W and Schwab M (1999) Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Horm Metab Res 31: 138–141
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wen, B., Deutsch, E., Marangoni, E. et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85, 2017–2021 (2001). https://doi.org/10.1054/bjoc.2001.2171
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2171
Keywords
This article is cited by
-
Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma
Journal of Hematology & Oncology (2020)
-
Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism
Nature Metabolism (2020)
-
Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician
Endocrine (2016)
-
Growth factor receptors signaling in glioblastoma cells: therapeutic implications
Journal of Neuro-Oncology (2009)
-
Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2008)